Pharma market access is not one decision. It is four.

Traditional pharma market access has been defined narrowly: win formulary position with the largest commercial plans and PBMs, secure Medicare Part D and Medicaid coverage, and hand the rest to field sales. That model made sense when the payer was the only real gatekeeper. It no longer is.

Today, access is shaped by at least four distinct stakeholders, each with its own economics and decision process: health plan sponsors (and the PBMs that manage pharmacy benefits for them), self-insured employers who ultimately fund most commercial coverage, health systems whose P&T committees and budgets decide what gets used in their facilities, and providers who prescribe, administer, and navigate the paperwork. A win with one and a miss with another still leaves patients without the therapy.

Plans and PBMs remain the foundation. They decide coverage, formulary tier, prior authorization criteria, step edits, and utilization management. Winning here means a clear value story, credible clinical and economic evidence, a pricing and contracting strategy that reflects rebate dynamics, and policy language that matches how the product will actually be used.

The common mistake is treating a favorable coverage decision as the finish line. Coverage criteria that are too narrow, or prior authorization that is too burdensome, can make a "covered" drug functionally inaccessible.

Roughly two-thirds of Americans with employer coverage are in self-funded plans. For those members, the employer — not the insurer — carries the financial risk, and increasingly the employer makes the final call on benefit design, specialty drug carve-outs, and which PBM exclusions to accept.

Employers think in terms of total cost of care, productivity, absenteeism, and workforce health — not just drug spend. A therapy that reduces hospitalizations or returns people to work has a story that a pure pharmacy-budget conversation misses. Engaging employers, benefits consultants, and employer coalitions directly can unlock access that plan negotiations alone will not.

Health systems and integrated delivery networks control access at the point of care. Their P&T committees decide what enters the formulary, their pharmacy leaders manage budgets and 340B economics, and their value-analysis teams weigh a new therapy against site-of-care costs and operational burden.

For physician-administered and hospital-initiated products, health system access often matters as much as payer coverage. Systems that operate in risk-based arrangements — ACOs, capitated contracts, provider-sponsored plans — also act like payers themselves, and need an evidence and economic story built for that dual role.

Even with coverage and formulary position in place, therapies stall when providers find them hard to prescribe, administer, or get paid for. Correct coding, clear billing guidance, predictable reimbursement for administration, and hub or patient-support services all determine whether a practice adopts a product or quietly avoids it.

Providers are also where the clinical case becomes real. Their experience feeds back into guidelines, real-world evidence, and payer policy — which is why provider access is a strategic input, not a downstream sales task.

The Wellguidant approach treats these four stakeholders as one connected system rather than separate workstreams. An integrated market access plan typically includes:

• One value narrative, four translations — the same evidence framed for plan medical directors, employer benefit leaders, health system P&T committees, and prescribers.
• Evidence planning built backward from what each stakeholder needs to see, so trials and real-world studies answer the right questions before launch.
• Pricing and contracting that account for PBM rebates, employer benefit design, health system acquisition costs, and provider margin together.
• Coding, coverage, and reimbursement readiness so that providers can bill cleanly from day one — see our pharma coding, coverage, and reimbursement guide.
• Policy and regulatory alignment — from FDA labeling through CMS policy — so access strategy reflects where the rules are heading, not just where they are.
• Sequenced engagement that uses early wins with one stakeholder to build momentum with the others.

This is what differentiates the plan from conventional payer-only strategies: it closes the gaps between stakeholders where launches most often lose momentum.

• Coverage secured, but utilization management blocks real use.
• PBM formulary wins undone by employer exclusions or carve-outs.
• Health system P&T review delayed by missing economic data.
• Providers underpaid for administration, so they avoid the product.
• Evidence built for FDA approval, not for payer or employer decisions.

For investors, the question is whether a commercial forecast rests on access that is realistic across all four stakeholders — not just a plausible payer assumption. Our due diligence work tests coverage, employer, health system, and provider assumptions on transaction timelines.